ORIC Pharmaceuticals followed in the footsteps of the other biotechs that have managed to make their public debut this month, selling more shares than it expected for a haul of $120 million.

The South San Francisco, CA-based company—whose name is an acronym for “overcoming resistance in cancer”—priced its IPO late Wednesday, offering 7.5 million shares at $16 apiece, the top of its anticipated pricing range.

Last month when ORIC (NASDAQ: ORIC) filed documents outlining its plans, it set a preliminary target of $86 million. Yesterday, it increased that to $94 million, anticipating an offering of 6.25 million shares in… Read more »